Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 4;13:746889. doi: 10.3389/fimmu.2022.746889

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Juneja, Kazmi, Mellace and Saidi

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Liver Transplant Patients Immunosuppression Therapy Protocol. IS, Immunosuppression; Tac, tacrolimus; MMF, mycophenolate mofetil; CP, cyclophosphamide; CyA, cyclosporin A. Based on “A Pilot study of operational tolerance with a regulatory T-cell-based therapy in living donor liver transplantation” published in Hepatology by Todo et al. (9). This figure demonstrates the step by step protocol for patients who received regulatory T-cell therapy after undergoing liver transplants from live donors. Participants were monitored using liver biopsies as their immunosuppressive treatments were tapered. Ultimately 7 out of the 10 participants were able to successfully withdraw immunosuppressive therapy. The remaining 3 participants experienced signs of mild rejection and resumed immunosuppressive therapy protocols (9).